TheraRadar
← Back
Data updated: Jun 28, 2026

CAPLIN

Generics

CAPLIN is a generic drug manufacturer focused on Cardiovascular, Infectious Disease, Respiratory. Key products include POTASSIUM PHOSPHATES.

1985
Since
48
Drugs
-
Trials
2
New Drugs (2yr)
Modality:
2 Small Molecules

CAPLIN's Key Drugs

CAPLIN's core commercial portfolio centers on BRIMONIDINE TARTRATE AND TIMOLOL MALEATE, SODIUM PHOSPHATES, POTASSIUM PHOSPHATES, spanning Cardiovascular and Infectious Disease — its most strategically important drugs approved in the last 15 years.

CAPLIN's Recent FDA Approvals

CAPLIN secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

CAPLIN's Therapeutic Areas

CAPLIN's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Infectious Disease, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 40%
6 drugs
Infectious Disease 20%
3 drugs
Respiratory 13%
2 drugs
Dermatology 13%
2 drugs
Neurology 13%
2 drugs

CAPLIN Pipeline Snapshot

Active clinical trials for CAPLIN across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • BRIMONIDINE TARTRATE AND TIMOLOL MALEATE leads revenue
  • 3 key drugs tracked

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling